FibroGen, Inc. (NASDAQ:FGEN) Short Interest Update

FibroGen, Inc. (NASDAQ:FGEN) was the recipient of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 8,090,000 shares, a growth of 8.4% from the May 31st total of 7,460,000 shares. Based on an average daily volume of 2,320,000 shares, the days-to-cover ratio is currently 3.5 days.

Insider Buying and Selling

In related news, insider Deyaa Adib acquired 22,123 shares of the firm’s stock in a transaction that occurred on Wednesday, June 12th. The stock was purchased at an average cost of $1.17 per share, for a total transaction of $25,883.91. Following the purchase, the insider now directly owns 82,123 shares of the company’s stock, valued at approximately $96,083.91. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of FGEN. Armistice Capital LLC raised its stake in shares of FibroGen by 23.7% in the fourth quarter. Armistice Capital LLC now owns 9,764,000 shares of the biopharmaceutical company’s stock worth $8,654,000 after purchasing an additional 1,872,000 shares during the last quarter. Pennant Investors LP acquired a new stake in FibroGen during the fourth quarter worth about $681,000. Public Employees Retirement System of Ohio grew its holdings in FibroGen by 1,472.7% during the third quarter. Public Employees Retirement System of Ohio now owns 176,593 shares of the biopharmaceutical company’s stock worth $152,000 after acquiring an additional 165,364 shares during the period. Lighthouse Investment Partners LLC acquired a new stake in FibroGen during the fourth quarter worth about $136,000. Finally, Algert Global LLC grew its holdings in FibroGen by 488.4% during the third quarter. Algert Global LLC now owns 161,550 shares of the biopharmaceutical company’s stock worth $139,000 after acquiring an additional 134,094 shares during the period. 72.71% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a research note on Monday, June 3rd.

FibroGen Stock Down 7.0 %

Shares of NASDAQ:FGEN opened at $0.69 on Thursday. FibroGen has a 52-week low of $0.33 and a 52-week high of $3.02. The stock has a market cap of $68.73 million, a price-to-earnings ratio of -0.28 and a beta of 0.71. The business has a 50-day moving average price of $1.13 and a 200-day moving average price of $1.41.

FibroGen (NASDAQ:FGEN) last announced its quarterly earnings data on Monday, May 6th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($0.02). The firm had revenue of $55.90 million during the quarter, compared to analysts’ expectations of $41.00 million. As a group, equities analysts anticipate that FibroGen will post -1.05 EPS for the current fiscal year.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.